This article was originally published in The Gray Sheet
Executive SummaryInks non-exclusive agreement to provide InterVentional Technologies with a "stent cover" for pre-clinical and clinical studies designed to evaluate how the material affects stent performance. Bio-Vascular also will provide covers in commercial quantities following regulatory approval. IVT is responsible for obtaining market clearance and evaluating the cover for impact on restenosis and perforation rates, as well as effects on downstream debris during placement. IVT's LP stent, which recently received the CE mark, already incorporates the cover
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.